Amgen-Horizon Deal May Signal FTC’s Return To Bargaining
September 13, 2023
By: Laura C. Onken
On Sept. 1, just over a week before trial was slated to begin, the Federal Trade Commission and several states agreed to settle their challenge to Amgen Inc.'s proposed acquisition of Horizon Therapeutics, allowing the transaction to close.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
The Empty Chair in Antitrust Conspiracy Cases
Webinar
Antitrust
2026 Concurrences International Mergers Conference
Speaking Engagement
Antitrust
USC Gould/Analysis Group Global Competition Law Thought Leadership Conference
Speaking Engagement
Antitrust
17th ACI Summit on Biosimilars & Innovator Biologics
Speaking Engagement
Intellectual Property
GCR Live: Europe 2026
Speaking Engagement
Antitrust
Fixing “Litigate the Fix”: Insights from the FTC’s Workshop
Axinn Viewpoints
Antitrust
How Public and Private Enforcers Approach Data Use in the Financial Services Sector in the United States and Beyond
Publications
Antitrust
20th Annual IBA Competition Mid-Year Conference
Speaking Engagement
Antitrust
Axinn Recognized in 2026 IAM Patent 1000 for Patent Litigation Excellence
Awards & Recognitions
Intellectual Property
Axinn Partners Named to Lawdragon 500 Leading Global Litigators 2026
News
Litigation & Trials
